Earnings History Data for bluebird bio (BLUE) - NYSE NASDAQ

To lookup another company type a stock symbol and press 'Go'. The overview will show the earnings release info that is available in TheStockCatalyst database for the company.

For historic stock the Extended Hours price data shown are from just before market open on the day of release for premarket earnings releases and of the day after release for afterhours earnings releases. The normal price data is from just before market close on the days of release for premarket releases and the day after release for afterhours releases.

See the full list of available companies here.

bluebird bio

Bluebird Bio, Inc. is a biotechnology company. It focuses on the development, manufacture and marketing of therapies for severe genetic disorders such as childhood cerebral adrenoleukodystrophy, neurodegenerative disorders and beta-thalassemia. The company operates in the U.S. and Europe. Bluebird Bio, Inc. is headquartered in Cambridge, Massachusetts.

Release Date	Time	Est. Time	Symbol	Name	Market Cap (M)	Rep. EPS	Est. EPS	Last years EPS	SeekingAlpha Headline	Price	Change	Ext. Hours Price	Ext. Hours Change	52 Week Range	Volume	Avg. Volume	Ext. Hours Volume
14-11-2024	PM		BLUE	bluebird bio	76.00	-0.31	-0.38	0.00	bluebird bio GAAP EPS of -$0.31 beats by $0.06, revenue of $10.61M misses by $8.07M [11/14/2024 7:01 AM]	0.3622	-0.01 (-3.75%)	0.37	-0.01 (-1.67%)	0.34 - 5.53	5,224,271	6,470,000	228,225
bluebird bio GAAP EPS of -$0.31 beats by $0.06, revenue of $10.61M misses by $8.07M [11/14/2024 7:01 AM] bluebird bio Q3 2024 Earnings Preview [11/13/2024 2:05 PM] Earnings Snapshot: bluebird bio reports mixed Q3, Q4 revenue outlook below consensus [11/14/2024 8:00 AM] bluebird bio says seeking more cash to achieve cash flow break-even [11/14/2024 1:17 PM]
27-09-2024	AH		BLUE	bluebird bio	93.00	-0.42	-0.40	0.00		0.5212	0.02 (3.33%)	0.52	0.01 (2.87%)	0.46 - 5.53	6,008,754	8,360,000	117,722
Bluebird: Q2 Earnings Snapshot [2024-09-27 04:40PM] bluebird bio Announces Completion of its Q2 2024 Form 10-Q Filing [2024-09-27 04:30PM]
09-05-2024	PM		BLUE	bluebird bio, Inc.	110.43	N/A	-0.47	0.21	bluebird bio reports Q1 results [5/9/2024 7:03 AM]	1.12	0.15 (14.92%)	1.02	0.05 (4.66%)	0.85 - 5.53	10,597,781	8,210,000	243,795
Bluebird bio spikes even as CRISPR leads in gene therapy rollout [5/9/2024 2:10 PM] bluebird bio reports Q1 results [5/9/2024 7:03 AM] bluebird bio Q1 2023 Earnings Preview [5/8/2024 11:39 AM]
07-11-2023	PM		BLUE	bluebird bio, Inc.	372.20	-0.66	-0.69	-0.92	bluebird bio GAAP EPS of -$0.66 beats by $0.01, revenue of $12.39M misses by $1.02M [11/7/2023 7:01 AM]	3.54	0.24 (7.27%)	3.45	0.15 (4.55%)	2.52 - 8.58	4,948,277	3,790,000	11,721
bluebird bio Q3 2023 Earnings Preview [11/6/2023 12:02 PM] bluebird bio GAAP EPS of -$0.66 beats by $0.01, revenue of $12.39M misses by $1.02M [11/7/2023 7:01 AM]
08-08-2023	PM		BLUE	bluebird bio, Inc.	412.88	-0.67	-0.72	-1.29	bluebird bio GAAP EPS of -$0.67 beats by $0.04, revenue of $6.89M misses by $4.36M [8/8/2023 7:03 AM]	3.90	0.30 (8.47%)	3.60	0.0 (0.00%)	2.78 - 8.58	10,521,274	3,460,000	60,618
bluebird bio Q2 2023 Earnings Preview [8/7/2023 12:18 PM] bluebird bio GAAP EPS of -$0.67 beats by $0.04, revenue of $6.89M misses by $4.36M [8/8/2023 7:03 AM] bluebird bio to sell stock to raise $125M [8/8/2023 9:43 AM]
09-05-2023	PM	7:00 AM ET (May 9)	BLUE	bluebird bio, Inc.	464.84	0.21	-0.54	-1.66	bluebird bio GAAP EPS of $0.21 beats by $0.52, revenue of $2.38B beats by $2.35B [5/9/2023 7:05 AM]	4.92	0.57 (12.99%)	4.11	-0.24 (-5.52%)	2.78 - 8.58	4,871,976	4,520,000	39,640
bluebird bio Q1 2023 Earnings Preview [5/8/2023 12:14 PM] bluebird bio GAAP EPS of $0.21 beats by $0.52, revenue of $2.38B beats by $2.35B [5/9/2023 7:05 AM] bluebird bio surges 14% on Q1 results, sickle cell candidate [5/9/2023 2:05 PM]
29-03-2023	PM	7:00 AM ET (Mar 29)	BLUE	bluebird bio	367.00	-0.57	-0.45	0.00	bluebird bio GAAP EPS of -$0.38 misses by $0.18, revenue of $0.06M misses by $15.34M [3/29/2023 7:04 AM]	3.15	-1.17 (-27.08%)	3.66	-0.66 (-15.28%)	2.87 - 8.58	18,230,140	4,480,000	298,541
bluebird bio Q4 2022 Earnings Preview [3/28/2023 1:00 PM] bluebird bio GAAP EPS of -$0.38 misses by $0.18, revenue of $0.06M misses by $15.34M [3/29/2023 7:04 AM] bluebird bio drops 11% on potential delay for sickle cell drug application [3/29/2023 9:02 AM]
04-08-2022	AH	4:05 PM ET (Aug 4)	BLUE	bluebird bio	289.00	-1.29	-1.31	0.00	bluebird bio GAAP EPS of -$1.36 misses by $0.07, revenue of $1.52M beats by $0.81M [8/4/2022 5:23 PM]	5.57	0.99 (21.62%)	4.57	-0.01 (-0.22%)	2.87 - 17.85	22,359,007	4,670,000	74,218
bluebird bio GAAP EPS of -$1.36 misses by $0.07, revenue of $1.52M beats by $0.81M [8/4/2022 5:23 PM] Bluebird bio gains as earnings update draws upgrade at Barclays [8/5/2022 11:10 AM] bluebird bio Reports Second Quarter 2022 Financial Results and Highlights Operational Progress [Aug-04-22 04:05PM] 1 Reason to Buy Bluebird Bio, and 1 Reason to Sell [Aug-03-22 10:53AM] Bluebird Bio (BLUE) Reports Q2 Loss, Lags Revenue Estimates [Aug-04-22 07:25PM]
09-05-2022	AH	4:30 PM ET (May 9)	BLUE	bluebird bio	290.00	-1.66	-1.26	0.00	bluebird bio GAAP EPS of -$1.66 misses by $0.30, revenue of $1.95M beats by $1.78M [5/9/2022 5:13 PM]	3.82	0.48 (14.56%)	3.43	0.10 (3.00%)	3.30 - 23.05	2,278,681	2,282,483	3,453
bluebird bio GAAP EPS of -$1.66 misses by $0.30, revenue of $1.95M beats by $1.78M [5/9/2022 5:13 PM] bluebird bio Reports First Quarter 2022 Financial Results and Highlights Operational Progress [May-09-22 04:05PM] Bluebird Bio (BLUE) Reports Q1 Loss, Lags Revenue Estimates [May-09-22 06:25PM]
04-03-2022	AH		BLUE	bluebird bio	388.00	-1.82	-1.82	0.00	bluebird bio GAAP EPS of -$1.83 misses by $0.07, revenue of $1.61M misses by $4.11M [3/4/2022 4:33 PM]	4.34	-0.65 (-13.10%)	4.30	-0.70 (-14.00%)	4.16 - 23.04	2,821,536	1,700,000	183,403
Bluebird bio sinks as finance chief resigns [3/7/2022 9:18 AM] bluebird bio Reports Fourth Quarter and Full Year 2021 Financial Results, Highlights Operational Progress and Provides Corporate Update [Mar-04-22 04:31PM] Bluebird Bio (BLUE) Reports Q4 Loss, Lags Revenue Estimates [Mar-04-22 05:45PM] Cash-crunched bluebird bio loses CFO [Mar-07-22 12:00PM] Why Bluebird Bio Stock Is Sinking Today [Mar-07-22 02:58PM]
05-11-2021	PM		BLUE	bluebird bio	1,678	-2.93	-2.72	0.00	bluebird bio EPS misses by $0.51, misses on revenue [11/5/2021 7:56 AM]	13.17	-3.14 (-19.23%)	17.75	1.44 (8.85%)	11.10 - 34.75	5,663,962	890,000	58,503
bluebird bio EPS misses by $0.51, misses on revenue [11/5/2021 7:56 AM] bluebird bio completes spin-off of cell therapy company 2seventy bio [11/4/2021 3:21 PM] Bluebird bio drops after Q3 earnings as oncology spin-off takes effect [11/5/2021 12:59 PM] bluebird bio Reports Third Quarter Financial Results and Recent Operational Progress [Nov-05-21 07:05AM] Cambridge gene therapy firm bluebird bio to move to Somerville [Nov-05-21 07:00AM] bluebird bio and Federal Realty to Establish Biotech Footprint at Assembly Row [Nov-05-21 06:58AM] Bluebird bio completes spinout of oncology business 2seventy bio [Nov-04-21 04:35PM] bluebird bio to Present New Gene Therapy Data at the 63rd American Society of Hematology (ASH) Annual Meeting and Exposition [Nov-04-21 09:00AM] bluebird bio Completes Planned Business Separation [Nov-04-21 07:00AM] Bluebird Bio (BLUE) Reports Q3 Loss, Lags Revenue Estimates [Nov-05-21 08:25AM]
09-08-2021	PM	7:00 AM ET (Aug 9)	BLUE	Bluebird Bio, Inc.	1,745	-3.58	-3.26	0.00	bluebird bio EPS misses by $0.32, misses on revenue [8/9/2021 7:02 AM]	18.15	-6.88 (-27.49%)	19.40	-5.63 (-22.49%)	18.11 - 66.12	8,665,068	820,000	403,598
bluebird bio EPS misses by $0.32, misses on revenue [8/9/2021 7:02 AM] bluebird bio stock plunges 24% after FDA clinical hold on eli-cel due to serious adverse event [8/9/2021 8:43 AM] Bluebird bio’s setback hurts AVROBIO and others focused on lentiviral gene therapies [8/9/2021 12:01 PM] Bluebird bio cut to market perform at SVB Leerink; says bullish thesis is “untenable" [8/9/2021 3:16 PM] bluebird bio Reports Second Quarter Financial Results and Provides Operational Update [Aug-09-21 07:00AM] Bluebird's stock falls 21% as it says it will focus on U.S. market for gene therapies, citing 'European payers' [Aug-09-21 08:47AM] Bluebird Bio (BLUE) Reports Q2 Loss, Misses Revenue Estimates [Aug-09-21 08:15AM] Bluebird Bio Stock Drops After Results, Plan to End Europe Operations [Aug-09-21 06:38AM] Why Bluebird Bio Stock Is Crashing Today [Aug-09-21 12:38PM] Bluebird Stock Crashes To 7-Year Low After FDA Pauses Gene Therapy Test [Aug-09-21 01:14PM]
05-05-2021	AH		BLUE	Bluebird Bio, Inc.	1,996	-3.07	-3.05	0.00	bluebird bio EPS misses by $0.08, beats on revenue [5/5/2021 4:59 PM]	29.68	0.47 (1.61%)	29.21	0.0 (0.00%)	24.24 - 72.50	1,036,062	870,000	1,975
bluebird bio Reports First Quarter Financial Results and Highlights Operational Progress [May-05-21 04:05PM] Bluebird Bio (BLUE) Reports Q1 Loss, Tops Revenue Estimates [May-05-21 06:35PM]
23-02-2021	AH		BLUE	bluebird bio, Inc.	1,770	-3.01	-3.02	-4.04	bluebird bio EPS misses by $0.05, misses on revenue [2/23/2021 4:56 PM]	25.93	0.31 (1.21%)	26.22	0.60 (2.34%)	24.24 - 77.68	3,216,294	4,392,859	33,515
bluebird bio EPS misses by $0.05, misses on revenue [2/23/2021 4:56 PM] bluebird bio earnings show high cash burn as FDA turns LentiGlobin suspension into a hold [2/23/2021 6:03 PM] The Gross Law Firm Announces Class Actions on Behalf of Shareholders of BLUE, TCDA and JFU [Feb-24-21 02:30PM] BLUE SHAREHOLDER FILING DEADLINE: Bernstein Liebhard LLP Reminds Investors of the Deadline to File a Lead Plaintiff Motion in a Securities Class Action Lawsuit Has Been Filed Against bluebird bio, Inc. [Feb-24-21 01:19PM] Glancy Prongay & Murray LLP Reminds Investors of Looming Deadline in the Class Action Lawsuit Against bluebird bio, Inc. (BLUE) [Feb-24-21 12:00PM] BLUE Shareholder Alert: Bronstein, Gewirtz & Grossman, LLC Reminds bluebird bio, Inc. Investors of Class Action and Encourages Shareholders to Contact the Firm [Feb-24-21 11:00AM] Is There Any Hope for bluebird bio Stock? [Feb-24-21 06:56AM] CLASS ACTION UPDATE for BLUE, BTBT and CLOV: Levi & Korsinsky, LLP Reminds Investors of Class Actions on Behalf of Shareholders [Feb-23-21 06:33PM] bluebird bio Reports Fourth Quarter and Full Year 2020 Financial Results and Highlights Operational Progress [Feb-23-21 04:05PM] LAWSUITS FILED AGAINST BLUE, XOM and EH - Jakubowitz Law Pursues Shareholders Claims [Feb-23-21 03:20PM] INVESTOR ACTION REMINDER: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against bluebird bio, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm [Feb-23-21 02:39PM] The Gross Law Firm Announces Class Actions on Behalf of Shareholders of BLUE, IRTC and FUBO [Feb-23-21 01:37PM] Deadline Reminder: Law Offices of Howard G. Smith Reminds Investors of Looming Deadline in the Class Action Lawsuit Against bluebird bio, Inc. (BLUE) [Feb-23-21 12:30PM] The Klein Law Firm Reminds Investors of Class Actions on Behalf of Shareholders of BLUE, BTBT and XOM [Feb-23-21 12:00PM] SHAREHOLDER DEADLINE ALERT: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against bluebird bio, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm [Feb-23-21 11:15AM] bluebird bio: Positive Resolution Of Clinical Hold Could Drive Asymmetrical Upside [Feb-23-21 05:38AM]
04-11-2020	AH		BLUE	bluebird bio, Inc.	3,610	-2.94	-3.07	-3.73	bluebird bio EPS beats by $0.08, misses on revenue [11/4/2020 5:07 PM]	48.73	-9.82 (-16.77%)	48.46	-10.09 (-17.23%)	38.95 - 99.36	7,219,848	673,392	104,425

05-08-2020	AH		BLUE	bluebird bio, Inc.	3,490	-0.36	-1.91	-3.55	bluebird bio EPS beats by $2.16, beats on revenue [8/5/2020 5:02 PM]	63.84	0.0 (0.00%)	64.00	0.16 (0.25%)	38.95 - 126.39	236,377	779,608	441